| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc. | Deramiocel (CAP-1002) - (INSPIRE) | COVID-19 | Phase 2 | Data Released | Intracoronary | COVID-19 |
| Cardiff Oncology Inc. | Onvansertib (PCM-075) and Irinotecan and 5-FU | Pancreatic ductal adenocarcinoma (PDAC) | Phase 2 | Data Released | Intravenous | Oncology |
| Cardiff Oncology Inc. | CRDF-004 | Metastatic colorectal cancer (mCRC) | Phase 2 | Data Released | Oral | Oncology |
| Cardiff Oncology Inc. | Onvansertib (PCM-075) and ZYTIGA (abiraterone acetate) | Prostate cancer | Phase 2 | Trial Discontinued | oral | Oncology |
| Cardiff Oncology Inc. | Onvansertib - (investigator initiated trial) | Small cell lung cancer (SCLC) | Phase 2 | Ongoing | Oral | Oncology |
| Cardiol Therapeutics Inc. | CardiolRx - (LANCER) | Cardiovascular disease (CVD) in COVID-19 pateints | Phase 2/3 | Oral | COVID-19 | |
| Cardiol Therapeutics Inc. | CardiolRx | Recurrent Pericarditis | Phase 2 | Ongoing | Oral | Cardiology |
| Cardiol Therapeutics Inc. | CardiolRx - (ARCHER) | Myocarditis | Phase 2 | Data Released | Oral | Cardiology |